Viatris reports third-quarter 2026 results

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2026 , Viatris Inc. ("Viatris" or the "Company") issued a press release reporting the Company's financial results for the period ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.¹

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

As previously announced, Viatris will host a conference call and live webcast today at 8:30 a.m.^{4 4}ET to review the Company's financial results for the period ended September 30, 2026.⁴

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1

Press release announcing the Company's financial results for the third quarter of 2026, dated November 5, 2026 .

104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VIATRIS INC.

Date: November 5, 2026 By: /s/ MATTHEW J. MALETTA

Matthew J. Maletta

Chief Legal Officer

Viatris Reports Third-Quarter 2026 Financial Results²

• Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion²

• Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan³

• Returns Approximately $717 Million of Capital to Shareholders Year to Date, Including Through Share Repurchases

• Advances Innovative Medicines Strategy with Planned Acquisition of Pacira BioSciences, Expected to Close by the End of November

• Raises 2026 Financial Guidance Midpoints for All Metrics⁵ [1]

PITTSBURGH – Nov. 5, 2026 – Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced its third-quarter 2026 financial results.

Executive Commentary

"Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business," said Scott A. Smith, CEO, Viatris . "Momentum across key areas of our base business, progress in our pipeline and the benefits of our enterprise-wide strategic review continue to strengthen our company. With the recent U.S. launch of Gwyn Lo, approvals of RYZUMVI in the U.S. and WAKIX in Japan, the potential upcoming approval and launch of fast-acting meloxicam and our recently announced agreement to acquire Pacira BioSciences, we are taking important steps to position Viatris for sustained revenue and earnings growth."

"We are very pleased with the operational momentum across our higher-margin businesses and continued focus on cost discipline, which led to strong overall third-quarter results," said Paul Campbell, Interim CFO, Chief Accounting Officer & Corporate Controller, Viatris . "Based on this performance and our confidence in the outlook for the rest of the year, we are once again raising the midpoints of our financial guidance ranges across all key metrics. Also, consistent with our disciplined and balanced capital allocation strategy, we continued returning additional value to shareholders in the quarter and expect the Pacira transaction to have minimal impact on our gross leverage ratio upon expected closing by the end of November."

[1] Viatris is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or U.S. GAAP diluted EPS (loss) or a quantitative reconciliation of its 2026 adjusted EBITDA or adjusted EPS guidance. U.S. GAAP net cash provided by operating activities for 2026 is estimated to be between $2.025 billion and $2.1 billion, with a midpoint of approximately $2.0625 billion. 2026 financial guidance ranges as provided on November 5, 2026, exclude the impact of any transaction-related and restructuring-related costs⁶ (as defined below) and acquired IPR&D for unsigned deals as they cannot be reasonably forecasted. 2026 financial guidance ranges also exclude any contribution from the planned acquisition of Pacira BioSciences. Please see "2026 Financial Guidance" and "Non-GAAP Financial Measures" for additional information.

2

Third-Quarter Results

Three Months Ended

September 30,

(Unaudited; in millions, except %s and per share amounts)

Total Revenues⁷

Net Sales by Product Category

Brands $ 2,461.4 $ 2,436.8 1% 1%

Generics

Adjusted Gross Profit (2)

$ 2,176.0 $ 2,104.4 3%

Adjusted Gross Margin (2)

U.S. GAAP Loss Per Share $ (0.28) $ (0.11) NM

Adjusted Net Earnings (2)

$ 821.4 $ 784.3 5%

Adjusted EPS (2)

$ 0.71 $ 0.67 6% 3%

EBITDA (2)

$ 937.5 $ 800.2 17%

Adjusted EBITDA (2)

$ 1,195.7 $ 1,154.6 4% 1%

U.S. GAAP Net Cash Provided by Operating Activities

$ 899.4 $ 744.9 21%

Capital Expenditures

___________

(1) See "Certain Key Terms and Presentation Matters" in this release for more information.

(2) Non-GAAP financial measures. See "Non-GAAP Financial Measures" for additional information.

(3) Excluding the impact of transaction-related and restructuring-related costs of $81 million, free cash flow for the three months ended September 30, 2026, was $895 million. Excluding the impact of transaction-related costs of $70 million, free cash flow for the three months ended September 30, 2025, was $728 million.

3

Nine Months Ended

September 30,

(Unaudited; in millions, except %s and per share amounts)

2026 2025 Reported Change Operational Change (1) (2)

Total Revenues

Net Sales by Product Category

Brands $ 7,212.3 $ 6,838.2 5% 3%

Generics

Adjusted Gross Profit (2)

$ 6,305.2 $ 5,952.4 6%

Adjusted Gross Margin (2)

57.2 % 56.2 %

U.S. GAAP Net Loss (3)

$ (267.7) $ (3,174.8) NM

U.S. GAAP Loss Per Share (3)

$ (0.23) $ (2.70) NM

Adjusted Net Earnings (2)

$ 2,324.0 $ 2,110.6 10%

Adjusted EPS (2)